

# OPTIMISING MOLECULAR DIAGNOSIS AND PRECISION THERAPY IN PATIENTS WITH ADVANCED NSCLC HARBOURING RARE ONCOGENIC TRANSLOCATIONS

## Chair

Zofia Piotrowska, Boston, MA, USA

## Co-Chair

Antonio Calles, Madrid, Spain

**WEDNESDAY, 20 MARCH 2024**

**18:15 - 19:45 CET, FORUM HALL**

<b>18:15</b>	<b>Welcome and introduction</b>	Zofia Piotrowska Boston, MA, USA
<b>18:25</b>	<b>Tissue and liquid-based next-generation sequencing diagnostics for patients with advanced NSCLC: Platforms, timings and issues with tissues</b>	Antonio Calles Madrid, Spain
<b>18:45</b>	<b>Molecular Reports in advanced NSCLC: How to optimise report structure, molecular tumour board input and actionability</b>	Ales Ryska Hradec Králové, Czech Republic
<b>19:05</b>	<b>Optimal therapeutic regimens for advanced NSCLC patients with rare oncogenic translocations (beyond ALK) and insights on resistance upon retesting</b>	Zofia Piotrowska Boston, MA, USA
<b>19:25</b>	<b>Q&amp;A and discussion</b>	All speakers
<b>19:40</b>	<b>Concluding remarks</b>	Antonio Calles Madrid, Spain

This educational activity is provided by ESMO  
and supported by Eli Lilly and Company.

*Lilly*

